P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC
Conditions: Adenocarcinoma of Lung; Lung Cancer Interventions: Drug: A: Oral Restorative Microbiota Therapy (RMT) Capsules; Drug: B: Oral Restorative Microbiota Therapy (RMT) Capsules; Drug: A: Durvalumab 1500 mg IV; Drug: B: Durvalumab 1500 mg IV; Drug: B: Cisplatin/pemetrexed or Carboplatin/pemetrexed Sponsor: Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Alimta | Cancer | Cancer & Oncology | Non-Small Cell Lung Cancer | Oral Cancer | Research